{'fraction_non_alphanumeric': 0.018782870022539443, 'fraction_numerical': 0.003756574004507889, 'mean_word_length': 5.795918367346939, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical outcomes after Nellix Endovascular Aneurysm Sealing.

The published evidence on clinical outcomes of Nellix Endovascular Aneurysm Sealing for elective abdominal aortic aneurysm repair has confirmed low procedural morbidity and reintervention rate. This early clinical experience with Nellix is encouraging, despite the device and procedural steps being in evolution, and patients being treated outside of the recommended instructions for use. The long-term follow-up of a treated patient cohort is now available and demonstrates low aneurysm-related mortality and morbidity. The initial experience with the commercially available Nellix device was captured in a multicenter report involving 171 patients and two independently monitored, company-sponsored device registries (EVAS Forward Global Trial and Forward US Investigational Device Exemption Trial). All three clinical studies report a 99% procedural technical success, low mortality, and persistent endoleak rate with re-intervention rates comparable to conventional EVR device registries. Nellix EVAS is applicable to a range of aneurysm anatomies, including patients with isolated of concomitant iliac artery aneurysms. The post-procedural imaging appearances after Nellix EVAS are unique due to the AAA sac polymer, change with time, but are now well understood.